<DOC>
	<DOC>NCT00034593</DOC>
	<brief_summary>Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.</brief_summary>
	<brief_title>A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. You must have at least one tumor that can be physically measured or scanned by xray. You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago. You may not have used an experimental medicine or device within the past month. Cancer that has spread to your brain. If you are unwilling or unable to take folic acid or vitamin B12 supplements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>transitional cell carcinoma of the urothelium</keyword>
</DOC>